BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.

OBJECTIVE Cushing disease (CD) results from excessive exposure to glucocorticoids caused by an adrenocorticotropic hormone-secreting pituitary tumor. Inadequately treated CD is associated with significant morbidity and elevated mortality. Multicenter data on CD patients treated in routine clinical practice are needed to assess treatment outcomes in this rare disorder. The study purpose was to describe the burden of illness and treatment outcomes for CD patients. METHODS Eight pituitary centers in four U.S. regions participated in this multicenter retrospective chart review study. Subjects were CD patients diagnosed at ≥18 years of age within the past 20 years. Descriptive statistical analyses were conducted to examine presenting signs, symptoms, comorbidities, and treatment outcomes. RESULTS Of 230 patients, 79% were female (median age at diagnosis, 39 years; range, 18 to 78 years). Length of follow-up was 0 to 27.5 years (median, 1.9 years). Pituitary adenomas were 0 to 51 mm. The most common presenting comorbidities included hypertension (67.3%), polycystic ovary syndrome (43.5%), and hyperlipidemia (41.5%). Biochemical control was achieved with initial pituitary surgery in 41.4% patients (91 of 220), not achieved in 50.0% of patients (110 of 220), and undetermined in 8.6% of patients (19 of 220). At the end of follow-up, control had been achieved with a variety of treatment methods in 49.1% of patients (110 of 224), not achieved in 29.9% of patients (67 of 224), and undetermined in 21.0% of patients (47 of 224). CONCLUSION Despite multiple treatments, at the end of follow-up, biochemical control was still not achieved in up to 30% of patients. These multicenter data demonstrate that in routine clinical practice, initial and long-term control is not achieved in a substantial number of patients with CD. ABBREVIATIONS BLA = bilateral adrenalectomy CD = Cushing disease CS = Cushing syndrome eCRF = electronic case report form MRI = magnetic resonance imaging PCOS = polycystic ovary syndrome.

[1]  Niki Karavitaki,et al.  Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. , 2016, The lancet. Diabetes & endocrinology.

[2]  L. Nieman,et al.  Cushing's syndrome , 2015, The Lancet.

[3]  A. Tabarin,et al.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. , 2015, The Journal of clinical endocrinology and metabolism.

[4]  M. Broder,et al.  Incidence of Cushing’s syndrome and Cushing’s disease in commercially-insured patients <65 years old in the United States , 2015, Pituitary.

[5]  F. Casanueva,et al.  Managing Cushing’s disease: the state of the art , 2014, Endocrine.

[6]  S. Chew,et al.  Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. , 2013, European journal of endocrinology.

[7]  E. Horváth-Puhó,et al.  Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. , 2013, The Journal of clinical endocrinology and metabolism.

[8]  G. Gamble,et al.  Mortality and morbidity in Cushing’s syndrome in New Zealand , 2011, Clinical endocrinology.

[9]  B. Swearingen,et al.  Health care resource use and costs among patients with cushing disease. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[10]  A. Klibanski,et al.  Delayed remission after transsphenoidal surgery in patients with Cushing's disease. , 2010, The Journal of clinical endocrinology and metabolism.

[11]  V. Montori,et al.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[12]  W. Ludlam.  Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement , 2008 .

[13]  R. Fahlbusch,et al.  Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. , 2008, Journal of neurosurgery.

[14]  O. Dekkers,et al.  Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. , 2007, The Journal of clinical endocrinology and metabolism.

[15]  Charles B. Wilson,et al.  Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. , 2004, The Journal of clinical endocrinology and metabolism.

[16]  C. Bhagat.  Diagnosis and Complications of Cushing's Syndrome: a Consensus Statement. , 2004 .

[17]  C Hagen,et al.  Incidence and late prognosis of cushing's syndrome: a population-based study. , 2001, The Journal of clinical endocrinology and metabolism.

[18]  A. Klibanski,et al.  Long-term mortality after transsphenoidal surgery for Cushing disease. , 1999 .

[19]  J. Etxabe,et al.  Morbidity and mortality in Cushing's disease: an epidemiological approach , 1994, Clinical endocrinology.

[20]  R. Pariente,et al.  Cushing's Syndrome , 1944, Definitions.